Yixi Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yixi Bao has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Zijing Liu
Department of Gastroenterology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China
16 shared publicationsYouwei Pu
Department of Clinical Laboratory, The Second Affiliated Hospital of Chongqing Medical University
8 shared publicationsShuang Yu
The Second Affiliated Hospital of Chongqing Medical University, China
7 shared publicationsHui Tian
Department of Clinical Laboratory, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
6 shared publicationsJie Xu
The Center for Clinical Molecular Medical Detection, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
6 shared publicationsTingting Long
The Second Affiliated Hospital of Chongqing Medical University, China
6 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1956695
Investigation of the ABO gene as a biomarker in breast invasive carcinoma using cancer profiling and blood type distribution
Introduction: Invasive breast carcinoma (BRCA) is one of the leading causes of cancer‑related mortality in women worldwide, highlighting the urgent need for novel prognostic biomarkers. The ABO gene has recently been implicated in various cancers. This study comprehensively investigated the expression pattern, clinical significance, and potential molecular mechanisms of ABO in BRCA. Method: Multi‑omics data from The Cancer Genome Atlas and Genotype‑Tissue Expression databases were utilized. Human breast cancer tissue samples and matched adjacent normal tissue samples were obtained from patients who did not receive preoperative chemotherapy or radiotherapy at the First Affiliated Hospital of Zhengzhou University; non‑tumor specimens were also collected. We delineated the expression profile of the ABO gene in breast cancer tissues compared with normal breast tissues and across different molecular subtypes. We further evaluated its diagnostic utility and prognostic significance, and explored potential molecular mechanisms underlying ABO‑associated phenotypes as well as the distribution of ABO blood types. Quantitative reverse transcription polymerase chain reaction was performed on an independent clinical cohort (n=49 pairs) for validation. Results: ABO expression was significantly downregulated in BRCA tissues compared with normal breast tissues. This low expression was associated with aggressive clinicopathological features, including human epidermal growth factor receptor 2‑positive status, estrogen receptor/progesterone receptor negativity, specific racial backgrounds, and basal‑like molecular subtypes. Functionally, ABO expression demonstrated substantial diagnostic value (area under the curve=0.812) and served as an independent prognostic factor for poor overall survival, disease‑specific survival, and progression‑free interval, although it showed limited predictive accuracy for 1‑, 3‑, and 5‑year survival rates. Mechanistically, gene set enrichment analysis linked low ABO expression to pathways involved in DNA replication and mitochondrial translation, and promoter hypermethylation may act as a potential regulatory mechanism underlying its downregulation. Reduced ABO expression in BRCA was validated in our independent clinical cohort. Discussion: The ABO gene may serve as a novel diagnostic biomarker in BRCA. Its downregulation is potentially driven by epigenetic silencing and is linked to tumor proliferation and metabolism.
- 2 November 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1956695
Open AccessInvestigation of the ABO gene as a biomarker in breast invasive carcinoma using cancer profiling and blood type distribution
Introduction: Invasive breast carcinoma (BRCA) is one of the leading causes of cancer‑related mortality in women worldwide, highlighting the urgent need for novel prognostic biomarkers. The ABO gene has recently been implicated in various cancers. This study comprehensively investigated the expression pattern, clinical significance, and potential molecular mechanisms of ABO in BRCA. Method: Multi‑omics data from The Cancer Genome Atlas and Genotype‑Tissue Expression databases were utilized. Human breast cancer tissue samples and matched adjacent normal tissue samples were obtained from patients who did not receive preoperative chemotherapy or radiotherapy at the First Affiliated Hospital of Zhengzhou University; non‑tumor specimens were also collected. We delineated the expression profile of the ABO gene in breast cancer tissues compared with normal breast tissues and across different molecular subtypes. We further evaluated its diagnostic utility and prognostic significance, and explored potential molecular mechanisms underlying ABO‑associated phenotypes as well as the distribution of ABO blood types. Quantitative reverse transcription polymerase chain reaction was performed on an independent clinical cohort (n=49 pairs) for validation. Results: ABO expression was significantly downregulated in BRCA tissues compared with normal breast tissues. This low expression was associated with aggressive clinicopathological features, including human epidermal growth factor receptor 2‑positive status, estrogen receptor/progesterone receptor negativity, specific racial backgrounds, and basal‑like molecular subtypes. Functionally, ABO expression demonstrated substantial diagnostic value (area under the curve=0.812) and served as an independent prognostic factor for poor overall survival, disease‑specific survival, and progression‑free interval, although it showed limited predictive accuracy for 1‑, 3‑, and 5‑year survival rates. Mechanistically, gene set enrichment analysis linked low ABO expression to pathways involved in DNA replication and mitochondrial translation, and promoter hypermethylation may act as a potential regulatory mechanism underlying its downregulation. Reduced ABO expression in BRCA was validated in our independent clinical cohort. Discussion: The ABO gene may serve as a novel diagnostic biomarker in BRCA. Its downregulation is potentially driven by epigenetic silencing and is linked to tumor proliferation and metabolism.
- 20 June 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 319 (Pt 1) , 145423
Immunoregulatory function and anticancer effects of Polygonatum sibiricum polysaccharides against hepatic carcinoma via macrophage phenotype modulation
- 20 June 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 319 (Pt 1) , 145423
Immunoregulatory function and anticancer effects of Polygonatum sibiricum polysaccharides against hepatic carcinoma via macrophage phenotype modulation
- Open Access
- 23 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1531394
A cross-sectional and longitudinal cohort study of creatinine-to-cystatin C ratio and cardiovascular disease risk in a middle-aged and elderly population
Background: The creatinine-to-cystatin C ratio (CCR) has recently been proposed as a proxy indicator for sarcopenia. It has been linked to a range of adverse outcomes. However, the relationship between the CCR and cardiovascular disease (CVD) is not widely recognized. This study used data from the China Health and Retirement Longitudinal Study to investigate the association between the CCR and CVD in a middle-aged and elderly population.Methods: The cross-sectional study and longitudinal cohort study included 10,614 and 6,720 passengers, respectively. The occurrence of CVD incidents was defined as self-reported health history or receipt of cardiac disease treatment. The CCR through creatinine (mg/dL) and cystatin C (mg/dL) were calculated and grouped by quartiles. Unadjusted and adjusted logistic regression models were employed to further explore the CCR-CVD relationships.Results: The findings of our study demonstrated a progressively significant reduction in the risk of CVD with an additional CCR. The cross-sectional cohort findings indicated a 21% reduction in the risk of CVD with every additional unit of CCR (OR=0.79, 95% CI, 0.73-0.84). In three logistic regression models, there was a significant association between CCR quartiles and a lower risk of CCR (p for trend <0.001). Further subgroup analyses revealed a 16% reduction in the incidence of CVD with each additional unit of CCR among individuals aged below 65 years (OR, 0.84; 95% CI, 0.78–0.91) and a 18% decline in CVD with each unit of CCR in married populations (OR, 0.82; 95% CI, 0.77–0.88). The findings of the Longitudinal Cohort Study indicated that for each unit increase in CCR, there was an 22% reduction in the risk of CVD (OR=0.78, 95% CI, 0.68-0.90). In logistic regression models adjusted for all co-dependent variables, the prevalence of CVD was reduced by 15%, 21%, and 41% as the number of CCR quartiles increased. This result was also verified by restricted cubic spline analysis.Conclusion: In conclusion, the correlation between an elevated CCR and a reduced risk of CVD in middle-aged and elderly populations has been established. Enhanced CCR levels may prove useful in predicting CVD occurrence in the elderly, thus representing a simple and effective biomarker.
- 23 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1531394
Open AccessA cross-sectional and longitudinal cohort study of creatinine-to-cystatin C ratio and cardiovascular disease risk in a middle-aged and elderly population
Background: The creatinine-to-cystatin C ratio (CCR) has recently been proposed as a proxy indicator for sarcopenia. It has been linked to a range of adverse outcomes. However, the relationship between the CCR and cardiovascular disease (CVD) is not widely recognized. This study used data from the China Health and Retirement Longitudinal Study to investigate the association between the CCR and CVD in a middle-aged and elderly population.Methods: The cross-sectional study and longitudinal cohort study included 10,614 and 6,720 passengers, respectively. The occurrence of CVD incidents was defined as self-reported health history or receipt of cardiac disease treatment. The CCR through creatinine (mg/dL) and cystatin C (mg/dL) were calculated and grouped by quartiles. Unadjusted and adjusted logistic regression models were employed to further explore the CCR-CVD relationships.Results: The findings of our study demonstrated a progressively significant reduction in the risk of CVD with an additional CCR. The cross-sectional cohort findings indicated a 21% reduction in the risk of CVD with every additional unit of CCR (OR=0.79, 95% CI, 0.73-0.84). In three logistic regression models, there was a significant association between CCR quartiles and a lower risk of CCR (p for trend <0.001). Further subgroup analyses revealed a 16% reduction in the incidence of CVD with each additional unit of CCR among individuals aged below 65 years (OR, 0.84; 95% CI, 0.78–0.91) and a 18% decline in CVD with each unit of CCR in married populations (OR, 0.82; 95% CI, 0.77–0.88). The findings of the Longitudinal Cohort Study indicated that for each unit increase in CCR, there was an 22% reduction in the risk of CVD (OR=0.78, 95% CI, 0.68-0.90). In logistic regression models adjusted for all co-dependent variables, the prevalence of CVD was reduced by 15%, 21%, and 41% as the number of CCR quartiles increased. This result was also verified by restricted cubic spline analysis.Conclusion: In conclusion, the correlation between an elevated CCR and a reduced risk of CVD in middle-aged and elderly populations has been established. Enhanced CCR levels may prove useful in predicting CVD occurrence in the elderly, thus representing a simple and effective biomarker.
- 23 October 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 282 (Pt 2) , 136818
Immunomodulatory effects of Fructus corni acidic polysaccharide and its selenium nanoparticles composites in hepatocellular carcinoma
- 23 October 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 282 (Pt 2) , 136818
Immunomodulatory effects of Fructus corni acidic polysaccharide and its selenium nanoparticles composites in hepatocellular carcinoma
- Open Access
- 26 August 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1413213
Targeted anti-angiogenesis therapy for advanced osteosarcoma
To date, despite extensive research, the prognosis of advanced osteosarcoma has not improved significantly. Thus, patients experience a reduced survival rate, suggesting that a reevaluation of current treatment strategies is required. Recently, in addition to routine surgery, chemotherapy and radiotherapy, researchers have explored more effective and safer treatments, including targeted therapy, immunotherapy, anti-angiogenesis therapy, metabolic targets therapy, and nanomedicine therapy. The tumorigenesis and development of osteosarcoma is closely related to angiogenesis. Thus, anti-angiogenesis therapy is crucial to treat osteosarcoma; however, recent clinical trials found that it has insufficient efficacy. To solve this problem, the causes of treatment failure and improve treatment strategies should be investigated. This review focuses on summarizing the pathophysiological mechanisms of angiogenesis in osteosarcoma and recent advances in anti-angiogenesis treatment of osteosarcoma. We also discuss some clinical studies, with the aim of providing new ideas to improve treatment strategies for osteosarcoma and the prognosis of patients.
- 26 August 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1413213
Open AccessTargeted anti-angiogenesis therapy for advanced osteosarcoma
To date, despite extensive research, the prognosis of advanced osteosarcoma has not improved significantly. Thus, patients experience a reduced survival rate, suggesting that a reevaluation of current treatment strategies is required. Recently, in addition to routine surgery, chemotherapy and radiotherapy, researchers have explored more effective and safer treatments, including targeted therapy, immunotherapy, anti-angiogenesis therapy, metabolic targets therapy, and nanomedicine therapy. The tumorigenesis and development of osteosarcoma is closely related to angiogenesis. Thus, anti-angiogenesis therapy is crucial to treat osteosarcoma; however, recent clinical trials found that it has insufficient efficacy. To solve this problem, the causes of treatment failure and improve treatment strategies should be investigated. This review focuses on summarizing the pathophysiological mechanisms of angiogenesis in osteosarcoma and recent advances in anti-angiogenesis treatment of osteosarcoma. We also discuss some clinical studies, with the aim of providing new ideas to improve treatment strategies for osteosarcoma and the prognosis of patients.
- Open Access
- 2 May 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (19) , 21144-21151
Green Synthesis of Gold Nanoparticles from Polygahatous Polysaccharides and Their Anticancer Effect on Hepatic Carcinoma through Immunoregulation
Hepatic carcinoma is one of the leading causes of morbidity and mortality among all cancers, but no effective treatment measures have been developed. Herein, polystyrene polysaccharide (PSP) extracted from Polygonatum was used to synthesize gold nanoparticles (PSP-AuNPs) by heating and reduction methods, and the characteristics of the PSP-AuNPs were detected after successful synthesis. In vitro, the immunoregulatory effects of PSP-AuNPs were studied by testing the concentrations of NO, TNF-α, and IL-12p70 in the culture media of PSP-AuNPs-treated RAW264.7 macrophages, and the effect of biocompatibility on the viability of RAW264.7 macrophages and L02 cells was studied via a CCK-8 assay. In vivo, tumor-bearing mice were established and treated with PSP-AuNPs, and the anticancer effects were studied by detecting trends in tumor volume, tumor inhibition rate, and tumor cell proliferation index. Immunoregulation was assessed by evaluating the serum levels of TNF-α and IL-10, the CD4+/CD8+ lymphocyte ratio in peripheral blood and the spleen and thymus indices; toxicity was investigated by measuring body weight, liver and renal function indices. The results showed that PSP-AuNPs could regulate immune function both in vitro and in vivo with almost no toxicity. PSP-AuNPs exhibited excellent anticancer effects on hepatic carcinoma in vivo. The anticancer effect could be strengthened, and the toxicity could be reduced by the combined use of PSP-AuNPs and ADM. In conclusion, PSP-AuNPs could be effective as a therapy and adjuvant therapy for treating hepatic carcinoma, providing potential treatment strategies for this disease.
- 2 May 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (19) , 21144-21151
Open AccessGreen Synthesis of Gold Nanoparticles from Polygahatous Polysaccharides and Their Anticancer Effect on Hepatic Carcinoma through Immunoregulation
Hepatic carcinoma is one of the leading causes of morbidity and mortality among all cancers, but no effective treatment measures have been developed. Herein, polystyrene polysaccharide (PSP) extracted from Polygonatum was used to synthesize gold nanoparticles (PSP-AuNPs) by heating and reduction methods, and the characteristics of the PSP-AuNPs were detected after successful synthesis. In vitro, the immunoregulatory effects of PSP-AuNPs were studied by testing the concentrations of NO, TNF-α, and IL-12p70 in the culture media of PSP-AuNPs-treated RAW264.7 macrophages, and the effect of biocompatibility on the viability of RAW264.7 macrophages and L02 cells was studied via a CCK-8 assay. In vivo, tumor-bearing mice were established and treated with PSP-AuNPs, and the anticancer effects were studied by detecting trends in tumor volume, tumor inhibition rate, and tumor cell proliferation index. Immunoregulation was assessed by evaluating the serum levels of TNF-α and IL-10, the CD4+/CD8+ lymphocyte ratio in peripheral blood and the spleen and thymus indices; toxicity was investigated by measuring body weight, liver and renal function indices. The results showed that PSP-AuNPs could regulate immune function both in vitro and in vivo with almost no toxicity. PSP-AuNPs exhibited excellent anticancer effects on hepatic carcinoma in vivo. The anticancer effect could be strengthened, and the toxicity could be reduced by the combined use of PSP-AuNPs and ADM. In conclusion, PSP-AuNPs could be effective as a therapy and adjuvant therapy for treating hepatic carcinoma, providing potential treatment strategies for this disease.
- 14 June 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (12) , 10813-10829
A pairwise immune gene model for predicting overall survival and stratifying subtypes of colon adenocarcinoma
Objectives There is increasing evidence for a close correlation between risk stratification, prognosis and the immune environment in colon adenocarcinoma (COAD). However, the efficacy of immunotherapy is different among different patients with COAD. Therefore, the current work tends to use immune-related gene to develop a gene-pair model to evaluate the COAD prognosis, and to develop a new method for risk stratification of COAD, which is conducive to better predict the immunotherapy effect of patients. Methods Specifically, from the TCGA and GEO (GSE14333 and GSE39582) databases, we first collected gene expression profiles, associated survival follow-up information of COAD patients. Through systematic bioinformatics analysis, we established a prognosis-related model of colon cancer with three pairs of "immune gene pairs", with uni- and multivariate and lasso cox regression analyses verifying the model stability. Most immune cells showed markedly different levels of infiltration between the two risk subgroups calculated by the model. More, single-cell RNA-seq analyses were also performed to validate the selected genes in the immune gene-pair model. Results A prognosis-related model of colon cancer with three pairs of "immune gene pairs" were built and validated by several datasets. The analysis of immune landscape of COAD revealed that low-risk subgroup obtained by the prognosis-related model for COAD can be further divided into three subclusters with different prognosis. Then, we applied the Tumor online Prognostic analyses Platform (ToPP) to construct a prognostic model using these five genes. Results show that APOD, ISG20 and STC2 are risk factors, while CXCL9 and IL7R are protection factors. We also found that only the five-gene model could also predict the prognosis of COAD patients, indicating the robustness of the gene-pair model. Among the five genes, including CXCL9, APOD, STC2, ISG20, and IL7R, in the gene-pair model, single-cell RNA sequencing reveals the high expression of CXCL9 and IL7R in inflammatory macrophages. Using cell–cell interaction and trajectory analysis, data indicate that CXCL9+/IL7R+ pro-inflammatory macrophages were capable of secreting and activating more anti-tumor pathways than CXCL9−/IL7R− pro-inflammatory macrophages. Conclusions In short, we have successfully developed an "immune gene pair" related model that can judge the prognostic status of patients with COAD and may contribute to risk stratification and evaluate potential beneficiaries of immunotherapy, providing new ideas for the anti-COAD management and therapy.
- 14 June 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (12) , 10813-10829
A pairwise immune gene model for predicting overall survival and stratifying subtypes of colon adenocarcinoma
Objectives There is increasing evidence for a close correlation between risk stratification, prognosis and the immune environment in colon adenocarcinoma (COAD). However, the efficacy of immunotherapy is different among different patients with COAD. Therefore, the current work tends to use immune-related gene to develop a gene-pair model to evaluate the COAD prognosis, and to develop a new method for risk stratification of COAD, which is conducive to better predict the immunotherapy effect of patients. Methods Specifically, from the TCGA and GEO (GSE14333 and GSE39582) databases, we first collected gene expression profiles, associated survival follow-up information of COAD patients. Through systematic bioinformatics analysis, we established a prognosis-related model of colon cancer with three pairs of "immune gene pairs", with uni- and multivariate and lasso cox regression analyses verifying the model stability. Most immune cells showed markedly different levels of infiltration between the two risk subgroups calculated by the model. More, single-cell RNA-seq analyses were also performed to validate the selected genes in the immune gene-pair model. Results A prognosis-related model of colon cancer with three pairs of "immune gene pairs" were built and validated by several datasets. The analysis of immune landscape of COAD revealed that low-risk subgroup obtained by the prognosis-related model for COAD can be further divided into three subclusters with different prognosis. Then, we applied the Tumor online Prognostic analyses Platform (ToPP) to construct a prognostic model using these five genes. Results show that APOD, ISG20 and STC2 are risk factors, while CXCL9 and IL7R are protection factors. We also found that only the five-gene model could also predict the prognosis of COAD patients, indicating the robustness of the gene-pair model. Among the five genes, including CXCL9, APOD, STC2, ISG20, and IL7R, in the gene-pair model, single-cell RNA sequencing reveals the high expression of CXCL9 and IL7R in inflammatory macrophages. Using cell–cell interaction and trajectory analysis, data indicate that CXCL9+/IL7R+ pro-inflammatory macrophages were capable of secreting and activating more anti-tumor pathways than CXCL9−/IL7R− pro-inflammatory macrophages. Conclusions In short, we have successfully developed an "immune gene pair" related model that can judge the prognostic status of patients with COAD and may contribute to risk stratification and evaluate potential beneficiaries of immunotherapy, providing new ideas for the anti-COAD management and therapy.